Reengineered Albumin-Paclitaxel Nanoparticles Remodeling Tumor Cell Death Pathways for Prevention of Chemotherapy-Induced Breast Cancer Metastasis
Source abstract
Abstract
Triple-negative breast cancer (TNBC) is characterized by its unfavorable prognosis and heightened propensity for metastasis. Despite paclitaxel (PTX) chemotherapy being a cornerstone of treatment, it can paradoxically promote metastasis by facilitating Padi4-mediated nuclear expulsion and triggering the RAGE/ERK pathway. In this investigation, we engineered a tumor-responsive nanoparticle platform (RAPG) capable of codelivering PTX, the Padi4 inhibitor GSK484, and a RAGE antagonist peptide (RAP). The RAPG nanoparticles exhibited redox-sensitive drug release, precise tumor localization, and deep tissue permeation. Mechanistically, RAPG suppressed histone citrullination, impeded RAGE/ERK signaling, and reinforced conventional apoptotic pathways. In both in vitro and in vivo assessments, RAPG attenuated epithelial-mesenchymal transition markers and reduced tumor invasiveness, circulating tumor cells, and lung metastasis, while enhancing treatment efficacy and prolonging survival. This study presents a promising strategy to counteract chemotherapy-induced metastasis in TNBC through concurrent inhibition of Padi4-mediated histone citrullination and RAGE/ERK signaling.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Cancer Research and Treatment · Curcumin's Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, School of Pharmaceutical Sciences, Key Laboratory of Smart Drug Delivery, Ministry of Education
Fudan University
Key Laboratory of Breast Cancer in Shanghai, Department of Breast Surgery
Fudan University Shanghai Cancer Center
Funding
Shanghai Municipal Youth Science and Technology Star Project · Ministry of Science and Technology of the People's Republic of China · Pingyuan Laboratory · ZJLab
References (38)
Show source-provided references
1. 10.3322/caac.2187110.3322/caac.21871 ↗
2. 10.1016/j.semcancer.2020.06.00510.1016/j.semcancer.2020.06.005 ↗
3. 10.1158/2159-8290.CD-18-117710.1158/2159-8290.CD-18-1177 ↗
4. 10.1186/s13058-020-01296-510.1186/s13058-020-01296-5 ↗
5. 10.1016/S0140-6736(05)66544-010.1016/S0140-6736(05)66544-0 ↗
6. 10.6004/jadpro.2021.12.2.1110.6004/jadpro.2021.12.2.11 ↗
7. 10.1016/j.annonc.2023.11.01610.1016/j.annonc.2023.11.016 ↗
8. 10.1126/scitranslmed.aan002610.1126/scitranslmed.aan0026 ↗
9. 10.1038/s41556-018-0256-310.1038/s41556-018-0256-3 ↗
10. 10.1038/s43018-023-00524-z10.1038/s43018-023-00524-z ↗
11. 10.1073/pnas.130836211010.1073/pnas.1308362110 ↗
12. 10.3892/mmr.2019.996810.3892/mmr.2019.9968 ↗
13. 10.1126/sciadv.abe377110.1126/sciadv.abe3771 ↗
14. 10.1111/bph.1353910.1111/bph.13539 ↗
15. 10.1074/jbc.M115.70239910.1074/jbc.M115.702399 ↗
16. 10.1158/1078-0432.CCR-12-022110.1158/1078-0432.CCR-12-0221 ↗
17. 10.1200/JCO.2014.59.529810.1200/JCO.2014.59.5298 ↗
18. 10.1016/j.nano.2015.08.00610.1016/j.nano.2015.08.006 ↗
19. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
20. 10.1097/CAD.0b013e32830f904610.1097/CAD.0b013e32830f9046 ↗
21. 10.1016/j.drup.2008.08.00510.1016/j.drup.2008.08.005 ↗
22. 10.1200/JCO.2005.04.93710.1200/JCO.2005.04.937 ↗
23. 10.1186/s40164-017-0066-510.1186/s40164-017-0066-5 ↗
24. 10.1016/S1470-2045(15)00489-110.1016/S1470-2045(15)00489-1 ↗
25. 10.1186/s12943-021-01373-z10.1186/s12943-021-01373-z ↗
26. 10.1016/j.jconrel.2022.06.04810.1016/j.jconrel.2022.06.048 ↗
27. 10.1002/adma.20160003810.1002/adma.201600038 ↗
28. 10.1021/acsami.6b1439010.1021/acsami.6b14390 ↗
29. 10.1016/j.jconrel.2010.01.03610.1016/j.jconrel.2010.01.036 ↗
30. 10.2147/OTT.S24164010.2147/OTT.S241640 ↗
31. 10.1021/acs.molpharmaceut.2c0078410.1021/acs.molpharmaceut.2c00784 ↗
32. 10.1177/1758835922110655810.1177/17588359221106558 ↗
33. Törmänen U. · Cancer Res. · 1995 · 55 · 5595
34. Leoncini L. · Am. J. Pathol. · 1993 · 142 · 755
35. 10.1038/nrc.2016.5810.1038/nrc.2016.58 ↗
36. 10.1200/JCO.1999.17.9.272810.1200/JCO.1999.17.9.2728 ↗
37. Aslakson C. J. · Cancer Res. · 1992 · 52 · 1399
38. 10.1002/0471142735.im2002s3910.1002/0471142735.im2002s39 ↗